Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr136.30 SEK
Change Today -1.80 / -1.30%
Volume 583.3K
As of 11:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Open
kr138.10
Previous Close
kr138.10
Day High
kr138.20
Day Low
kr135.70
52 Week High
05/11/15 - kr145.90
52 Week Low
10/16/14 - kr65.25
Market Cap
36.9B
Average Volume 10 Days
1.0M
EPS TTM
kr0.63
Shares Outstanding
270.4M
EX-Date
--
P/E TM
216.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; Xiapex for the treatment of Peyronie’s disease; and Yondelis for the treatment of a type of cancer. The company also offers Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. In addition, it provides Aloxi, Betapred, ChondroCelect, Collatamp, Cometriq, Defibrotide, Erwinase, Ferriprox, Fosinopril, Kepivance, Megestrol, Ruconest, and Willfact for the treatment of rare diseases. Further, the company’s rFVIIIFc and rFIXFc are development projects in pipeline for the treatment of hemophilia; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002 is in Phase I clinical trials. It also manufactures drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A. The company has an agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

621 Employees
Last Reported Date: 05/6/15

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.4M
Compensation as of Fiscal Year 2014.

swedish orphan biovitrum ab (SOBI) Key Developments

Swedish Orphan Biovitrum AB (publ) Reports Earnings Results for the First Quarter of 2015; Reaffirms Earnings Guidance for Full Year 2015

Swedish Orphan Biovitrum AB (publ) reported earnings results for the first quarter of 2015. For the quarter, revenues totalled SEK 865 million against SEK 573 million a year ago. EBITA was SEK 172 million against EBITA loss of SEK 288 million a year ago. EBITA excluding write-offs was SEK 172 million against SEK 37 million a year ago. EBIT was SEK 102 million against EBIT loss of SEK 358 million a year ago. Profit for the period was SEK 106 million against loss for the period of SEK 329 million a year ago. The company continues to expect total revenues for the full year 2015 to be in the range of SEK 2,800 million to SEK 3,000 million, and gross margin to be in the range of 58%-60%. The company expects EBITA to be in the range of SEK 300 million to SEK 400 million.

Swedish Orphan Biovitrum AB, Q1 2015 Earnings Call, May 06, 2015

Swedish Orphan Biovitrum AB, Q1 2015 Earnings Call, May 06, 2015

Pfizer To Acquire Swedish Orphan Biovitrum

As per reports Swedish Orphan Biovitrum AB (OM:SOBI) had received an offer to be acquired earlier this week. It has been revealed that the preliminary offer had come from Pfizer Inc. (NYSE:PFE). The price that Pfizer has offered could not be learned. Spokesmen for both Sobi and Pfizer declined to comment. Pfizer Chief Executive Officer Ian Read said on Tuesday during an earnings call that he was open to deals and was "agnostic" about the size of acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr136.30 SEK -1.80

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.52 EUR +0.315
Oxford Biomedica PLC 10.25 GBp -0.25
Veloxis Pharmaceuticals A/S kr1.02 DKK +0.02
View Industry Companies
 

Industry Analysis

SOBI

Industry Average

Valuation SOBI Industry Range
Price/Earnings 100.0x
Price/Sales 13.1x
Price/Book 8.1x
Price/Cash Flow 230.9x
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit www.sobi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.